Physicians and menstruating women often ask pharmacists for recommendations about menstrual cycle–related problems. Progesterone and medroxyprogesterone may provide physiology-based treatment, but official indications in menstruating women in Canada are minimal.
Objectives:
To describe pharmacists' responses to vignette-based questions about the treatment of common clinical problems in menstruating women and review evidence-based therapies.
Methods:
A pharmacist interviewer administered an 11-item questionnaire to a random sample of community pharmacists. Questions were based on clinical vignettes in adolescent, pre- and perimenopausal women and related to heavy flow, polycystic ovary syndrome, premenopausal osteoporosis, perimenopausal night sweats and side effects/contraindications for estrogens and progesterone/progestins.
Results:
The participation rate was 58%, including equal numbers of male and female pharmacists. Seventy-two percent indicated that they would treat menorrhagia in an anemic 13-year-old with oral contraceptives — 21% would recommend ibuprofen and 86% iron. Half recommended that a 35-year-old smoker with heavy flow and acne stop oral contraceptives, but the other 50% recommended a switch to an oral contraceptive with cyproterone. For premenopausal osteoporosis, the majority recommended calcium and vitamin D, but 53% endorsed oral contraceptives — only 7% suggested cyclic medroxyprogesterone. For night sweats, the majority recommended progesterone/progestin in a regularly menstruating 42-year-old woman. Estrogens are contraindicated with past thrombosis and/or breast cancer family history, and they could cause nausea; 50% of pharmacists also attributed these adverse effects to progesterone/progestins.
Conclusions:
Community pharmacists vary widely in their treatment choices for common pre- and perimenopausal women's menstrual cycle–related problems. The evidence in support of most recommendations is minimal or lacking.
Get full access to this article
View all access options for this article.
References
1.
ShepherdJEBoppJ.Pharmacy-based care for perimenopausal and postmenopausal women. J Am Pharm Assoc (Wash)2002;42:700–11.
2.
Prometrium product monograph. In: RepchinskyC, ed. Compendium of pharmaceuticals and specialties. 9th ed.Ottawa (ON): Canadian Pharmacists Association; 2007. p. 1921–3.
3.
Medroxyprogesterone product monograph. In: RepchinskyC, ed. Compendium of pharmaceuticals and specialties. 9th ed.Ottawa (ON): Canadian Pharmacists Association; 2007. p. 1937–9.
4.
RossouwJEAndersonGLPrenticeRL. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33.
5.
AndersonGLLimacherMAssafAREffects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA2004;291:1701–12.
6.
FraserI.S.Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol1990;30:353–6.
7.
PriorJCVignaYMBarrSICyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Med1994;96:521–30.
8.
DennersteinLSpencer-GardnerCGottsGProgesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J1985;290:1617–21.
9.
FriessETagayaHTrachselLProgesterone-induced changes in sleep in male subjects. Am J Physiol1997;272:E885–E891.
10.
SchusslerPKlugeMYassouridisAProgesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology2008;33:1124–31.
11.
HolzerGRieglerEHonigsmannHEffects and side-effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study. Br J Dermatol2005;153:626–34.
12.
PriorJ.C.Ovulatory disturbances: they do matter. Can J Diagnosis1997;February:64–80.
13.
SantoroNBrownJRAdelTCharacterization of reproductive hormonal dynamics in the perimenopause. J Clin Endocrinol Metab1996;81:1495–501.
14.
PriorJ.C.The ageing female reproductive axis II: ovulatory changes with perimenopause. In: ChadwickDJGoodeJA, eds. Endocrine facets of ageing. Chichester (UK): John Wiley and Sons Ltd; 2002. p. 172–86.
15.
HaleGEZhaoXHughesCLEndocrine features of menstrual cycles in middle and late reproductive age and the menopausal transition classified according to the Staging of Reproductive Aging Workshop (STRAW) staging system. J Clin Endocrinol Metab2007;92:3060–7.
16.
MetcalfMGMacKenzieJ.A.Menstrual cycle and exposure to estrogens unopposed by progesterone: relevance to studies on breast cancer incidence. J Endocrinol1985;104:137–41.
17.
O'ConnorKAFerrellRJBrindleETotal and unopposed estrogen exposure across stages of the transition to menopause. Cancer Epidemiol Biomarkers Prev2009;18:828–36.
18.
MoenMHKahnHBjerveKSMenometrorrhagia in the perimenopause is associated with increased serum estradiol. Maturitas2004;47:151–5.
19.
KaufertPAGilbertPTateR.Defining menopausal status: the impact of longitudinal data. Maturitas1987;9:217–26.
20.
TuppurainenMHonkanenRKrögerHOsteoporosis risk factors, gynaecological history and fractures in perimenopausal women — the results of the baseline postal enquiry of the Kupio Osteoporosis Risk Factor and Prevention Study. Maturitas1993;17:89–100.
21.
CasperRFDodinSReidRLThe effect of 20 μg ethinyl estradiol/1 mg norethindrone acetate (Minestrin), a low-dose oral contraceptive, on vaginal bleeding patterns, hot flashes, and quality of life in symptomatic perimenopausal women. Menopause1997;4:139–47.
22.
LeeJ.R.Osteoporosis reversal — the role of progesterone. Int Clin Nutr Rev1990;10:384–91.
PeabodyJWLuckJGlassmanPComparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA2000;283:1715–22.
25.
VeloskiJTaiSEvansASClinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual2005;20:151–7.
26.
SilcockJMoffettJKEdmondsonHDo community pharmacists have the attitudes and knowledge to support evidence based self-management of low back pain?BMC Musculoskelet Disord2007;8:10.
27.
NewcombeR.G.Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med1998;17:873–90.
28.
GroverS.Bleeding disorders and heavy menses in adolescents. Curr Opin Obstet Gynecol2007;19:415–9.
29.
VollmanR.F.The menstrual cycle. In: FriedmanEA, ed. Major problems in obstetrics and gynecology. Vol. 7. Toronto (ON): W.B. Saunders Company; 1977. p. 11–193.
LethabyAIrvineGCameronI.T.Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev2008;(1):CD001016.
32.
LethabyAAugoodCDuckittK.Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev2002;(1):CD000400.
33.
IyerVFarquharCJepsonR.Oral contraceptive pills for heavy menstrual bleeding. Cochrane Database Syst Rev2000;(2):CD000154.
34.
VesseyMPainterRYeatesD.Mortality in relation to oral contraceptive use and cigarette smoking. Lancet2003;362:185–91.
35.
DanielMMartinADDrinkwaterD.T.Cigarette smoking, steroid hormones, and bone mineral density in young women. Calcif Tissue Int1992;50:300–5.
36.
IrvineGACampbell-BrownMBLumsdenMARandomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol1998;105:592–8.
37.
DanielKLRamirezM.Polycystic ovary syndrome: a review. US Pharmacist2007;32(9):HS3–HS15.
38.
SpritzerPMLisboaKOMattielloSSpironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol (Oxf)2000;52:587–94.
39.
VelazquezEAcostaAMendozaS.G.Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol1997;90:392–5.
40.
HonkanenRTuppurainenMKrogerHAssociations of early premenopausal fractures with subsequent fractures vary by sites and mechanisms of fractures. Calcif Tissue Int1997;60:327–31.
41.
CooperCHannafordPCroftPOral contraceptive pill use and fractures in women: a prospective study. Bone1993;14:41–5.
42.
PriorJCKirklandSAJosephLOral contraceptive agent use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ2001;165:1023–9.
43.
RideoutCABarrSIPriorJ.C.Clinical eating disorders and subclinical disordered eating: implication for bone health. In: BonjourJP, ed. Nutritional aspects of bone health. London (UK): Royal Chemistry Society; 2003. p. 611–44.
44.
SamuelssonEHedenmalmKPerssonI.Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives — an approach to specifying rates. Eur J Epidemiol2005;20:509–16.
45.
DingerJCHeinemannLAKuhl-HabichD.The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception2007;75:344–54.
46.
AbeOAsaishiKIzuoMEffects of medroxyprogesterone acetate therapy on advanced or recurrent breast cancer and its influences on blood coagulation and the fibrinolytic system. Surg Today1995;25:701–10.
47.
PriorJ.C.Clearing confusion about perimenopause. BC Med J2005;47:534–8.
48.
PriorJ.C.Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev1998;19:397–428.
49.
LeonettiHBLongoSAnastiJ.N.Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol1999;94:225–8.
50.
FournierABerrinoFClavel-ChapelonF.Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat2008;107:103–11.
51.
WHO collaborative study of neoplasia and steroid contraceptives. Breast cancer and depot-medroxyprogesterone acetate: a multinational study. Lancet1991;338:833–8.
52.
ChangKJLeeTTLinares-CruzGInfluence of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fertil Steril1995;63:785–91.
53.
FoidartJMColinCDenooXEstradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril1998;69:963–9.
54.
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet1996;347:1713–27.
55.
ChlebowskiRTHendrixSLLangerRDInfluence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA2003;289:3243–53.
56.
TremollieresFAStrongDDBaylinkDProgesterone and promogestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh)1992;126:329–37.
57.
PriorJCNielsenJDHitchcockCLMedroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond)2007;112:517–25.
58.
TremollieresFAPouillesJMRibotC.Effect of long-term administration of progestogen on post-menopausal bone loss: results of a two-year, controlled randomized study. Clin Endocrinol (Oxf)1993;38:627–31.
